Image source: The Motley Fool.
Q2 2019 Earnings Call
Aug 6, 2019, 10:00 a.m. ET
- Prepared Remarks
- Questions and Answers
- Call Participants
Good day and welcome to the Tenet Healthcare Second Quarter 2019 Earnings Call. [Operator Instructions] At this time, I would like to turn the conference over to Brendan Strong Vice President of Investor Relations. Please go ahead.
Good morning. The slides referred to in today’s call are posted on the company’s website. Please note the cautionary statement on forward-looking information included in the Slides. In addition, please note that certain statements made during our discussion today, constitute forward-looking statements. These statements relate to future events including but not limited to statements with respect to our business outlook and forecast our future earnings and financial position and corporate actions. These forward-looking statements represent management’s current expectations based on currently available information as for the outcome and timing of future events, but by their nature address matters that are uncertain. Actual results and plans could differ materially from those expressed in any forward-looking statement. For more information, please refer to the risk factors discussed in Tenet’s most recent Form 10-K and subsequent SEC filings. Tenet assumes no obligation to update any forward-looking statements or other information that speak as of the respective dates. And you’re cautioned that not to put undue reliance on these forward-looking statements.
I’ll now turn the call over to Ron Rittenmeyer, Tenet’s Executive Chairman and CEO, Ron.
Thanks, Brendon, and good morning. Reflecting on the second quarter. I’m really pleased with the performance across the entire enterprise. The continued improvements we have noted across each business led by our quality initiatives, supported by our innovative and engaging marketing programs and executed by our teams in every facility have established a new baseline for performance. We are not declaring victory nor are we slowing down the transformation. It is being driven by a change in the culture, which we have begun and we will continue as we improve performance focused on generating a better cash profile and preparing Conifer for a very successful spin.
Let’s touch on a few of the key items in the quarter. We delivered adjusted EBITDA growth in each of our operating segments. We exceeded the midpoint of our adjusted EBITDA outlook. One more time we beat consensus estimates for revenue, EBITDA and importantly EPS. We had a clear and meaningful improvement in our hospital volumes. USPI delivered a very strong quarter with solid increases in surgical volumes. And Conifer, despite all the uncertainties and changes with our future, generated double-digit EBITDA growth, a 540 basis points of margin improvement, reflecting the continued ongoing work to tighten the cost and service structure of the company.
Across Tenet, leadership changes have continued as part of our ongoing commitment to instill accountability and performance improvement. Some of the more recent changes included a new CFO at USPI, the appointment of interim CEO at Conifer and several new leaders in hospital operations in San Antonio, South Florida, Massachusetts as well as our headquarters' operation support teams. We’ve also announced the addition of a new board member Chris Lynch, who has significant financial akum and great experience working and serving on Boards in highly regulated industries. Chris will officially join the Board tomorrow and we look forward to his contributions. This is in line with our announced Board refreshment that we started in 2018 and to-date we have changed the Board by over 50% in less than two years with highly qualified and diverse members. It’s equally important to note that during these changes, our overall quality continues to improve across all of our Tenet hospitals and USPI facilities. Infection rates have steadily declined, while other important measures continue to improve. We continue to emphasize our commitment to quality, ethics and compliance as foundational parts of our transformation.
Our Q2 financial and clinical results were also very positive. In our hospitals, admissions — adjusted admissions and emergency room visits grew between 2% and nearly 3.5%. This quarter, we delivered admission growth in 18 of our 20 markets and we’re pleased about the significant improvement in our growth trajectory, and have confidence that we’re making the needed changes to improve the service levels, competitive positioning and financial profile of the hospital portfolio. This improvement is a type of performance that you can deliver with the right leadership, focus and accountability.
USPI had another great quarter with the continued volume and pricing growth in both surgical and non-surgical platforms. The acquisition pipeline remains robust as do our plans for continued de novo development. We added two health system partners in the second quarter and we acquired five surgery centers. We also opened four de novo surgery centers and two urgent care centers with a very strong pipeline of de novos for the rest of the year.
In Tenet and in USPI, our continued focus on recruiting top physicians and the community built on care marketing program across to our operations are critical to our success. We are working on our service line portfolios across both businesses and are ensuring these are tailored to the needs of our various communities. We believe our best referral is our patients, doctors and our employees who live and work in our communities.
Conifer set another record for quarterly performance achieving the highest quarterly EBITDA and EBITDA margin in its history. Conifer has great opportunities ahead, and there is a lot of excitement in the organization about the changes that we’re about to embark on. I also want to mention, as I stated in the Conifer release that we’re reconfirming our 2019 outlook for revenue, adjusted EBITDA and adjusted EPS.
But before I turn this over to Dan, I really need to comment on the terrible tragedies we’ve all witnessed this past weekend. We are the second largest private employer in El Paso, with over 5,000 employees from every part of our company, who have been impacted in so many ways. We cover for acute care hospitals and over 50 access points, including outpatient centers and physician clinics. The response to the El Paso tragic situation by Tenet medical and support teams was excellent. And I also want to mention the amazing response by HCA’s Del Sol Medical Center and the University Medical Center as well as all of the first responders who raised into danger. These individuals who live and work every day in El Paso showed what teamwork and amazing commitment means in a time of crisis. The Tenet family is deeply saddened by the events that have occurred, and we view El Paso as part of our family and will stand with them during this difficult and tragic time.
So the Tenet Healthcare Foundation, we’re announcing a donation of $100,000 to the El Paso Community Victim Fund that’s been set up for the shooting victims. And we will also match up to an additional $50,000 of donations made to the Tenet Healthcare Foundation by our employees, vendors and others throughout the Tenet enterprise, which we will then send directly to this El Paso Community Victims Fund. We are very proud of our teams in El Paso, and we will support them and their families during this very difficult time.
So with that, Dan — I’ll turn it over to Dan now, so he can discuss the highlights. Dan?
Thanks, Ron, and good morning, everyone. Let’s begin with volumes, the improvement in our volume growth is noteworthy, representing a sharp improvement from recent trends. Our adjusted EBITDA of $657 million was above the midpoint of our outlook range, despite $13 million of additional expense due to a decline in the treasury rates. Adjusted EPS was $0.56 also above the midpoint of our range. Our hospital segment generated $347 million of EBITDA. USPI’s EBITDA was up 8.4% and EBITDA less facility level NCI was up 9.1% after adjusting for the divestiture of Aspen, our former UK business. Conifer’s EBITDA was a record $103 million with margins up 540 basis points to 29% and adjusted free cash flow was $191 million this quarter.
Turning to Slide 5, hospital volumes were very strong this quarter. Admissions increased 3.3% and adjusted admissions were up 2.2%. Tom and our hospital teams have achieved significant volume growth in a short amount of time. This was the strongest volume quarter that we have delivered since the period immediately following the expansion of coverage under the Affordable Care Act. Revenue per adjusted admission was strong too, up 3.4%. Cost per adjusted admission were up 3.5% with about 60 basis points of this cost growth due to additional expense as a result of a decline in treasury rates. We are excited about the improving volumes and we will continue our aggressive work to achieve additional cost efficiencies over the next few quarters.
Moving to our ambulatory business on Slide 6. In our surgical business, revenue grew 5.2% on a same facility systemwide basis, with cases up 2.6% and revenue per case up 2.5%. In the non-surgical business, which represents our urgent care and freestanding imaging centers, revenue increased 8%. EBITDA on ambulatory segment grew 8.4% to $207 million and EBITDA less facility level NCI increased 9.1%. These growth rates exclude the $7 million of earnings that Aspen generated in the second quarter of last year.
Let’s now talk about Conifer on Slide 8. Conifer delivered another strong quarter with $103 million of EBITDA and a 29% margin. Conifer second quarter results included $13 million of annual performance incentive revenue as we met or exceeded performance benchmarks for customers over the past year. These are annual incentives and they will not recur in the back half of this year. However, Conifer has the opportunity to earn these incentives again next year.
Moving to our outlook, we are reconfirming the key components of our outlook for 2019, including our views on revenue and EBITDA by segment, adjusted EPS and adjusted free cash flow. Additional details on our 2019 outlook are contained on Slides 9 through 12.
Finally, I like to provide an update on the California Provider Fee program. We now believe we will be able to start recognizing revenue under the new program in the third quarter of this year. Our expectation now is that we will report approximately $65 million of revenue under the new program in both the third and fourth quarters of this year. Our previous annual estimate of $260 million of revenue for this year remains unchanged.
In summary, we delivered a sharp improvement in volume growth in our hospitals. We generated solid financial results with EBITDA and EPS in the upper half of our outlook range. USPI continues to produce strong and consistent earnings with solid volume growth. Conifer achieved the strongest financial quarter in its history, and we have reiterated our outlook for 2019.
Let me now turn the call back to Ron.
Thanks, Dan. I’d just like to close out by saying we really did have another solid quarter, with growth in each operating segment. We were executing against the plans in making solid progress. We do remain focused on performance, operations and people, and while we’re pleased, we also know we have more to accomplish. Aligning the organization around accountability and a set of core goals is helping to build a much stronger path forward for our future.
So with those comments, I’d like to turn it over now for questions. So Brendan.
So Mary. Please go ahead.
Questions and Answers:
Thank you, [Operator Instructions]. We will now take our first question from Josh Raskin of Nephron Research. Please go ahead.
Hi, thanks. Good morning. I wanted to start, I guess, on the volumes and it sounded like it was pretty broad based with 18 of the 20 markets. I know you made some commentary around Detroit, Chicago last quarter. So wondering where those fell out, but maybe just a little bit more color geographically and/or by service line where you saw some of that strength. And then I guess — also connected to that would be 3Q, where are you guys in July and you’ve got an extra workday, things like that. Is it fair to assume you’re expecting this to continue into the near future?
Saum do you want to — OK, go ahead.
Yes, just real briefly, as we indicated, it was broad based. We would refrain from commenting on individual markets at this point. We had broad based volume growth. As you saw, we had strength on the surgical side. We had greater strength on the medical side. Most of the benefit that we’re seeing in the markets is really coming back to the work we’ve been doing on managing our continuum of care, improving access in the hospitals, some of the initiatives we’ve had around scheduling efficiency in the operating rooms and procedure-based rooms in the hospitals and obviously the clinical capacity that we’re adding, and technology investments that we’re making will play out over a longer period of time, but we’re starting to see some of the benefits of that already. But it was broad based volume improvement.
And, Josh, this is Dan, the mix was good too, particularly on the commercial volume trends as well.
But no specifics on Detroit or Chicago this quarter.
Chicago we’ve divested Chicago, so it’s no longer in our same hospital fantastic [Ph]. And no there’s nothing to comment upon related to Detroit.
We will now take our next question from Ralph Giacobbe of Citi. Please go ahead.
Thanks. Good morning. First question, just if you can give us a better sense of same-facility EBITDA growth or margin performance and anything hindering that as maybe we didn’t see as much sort of pull through as we would have thought from the 5.7% organic top line?
Hey, Ralph. It’s Dan. Good morning. Yeah, actually we did see the pull-through. We did have to absorb $13 million of additional expense as a result of decline in treasury rate. So our overall EBITDA, if you exclude the additional discount rate impact, it was $670 million, which means at the top end of our range, so we saw a pretty good pull-through. In terms of margins on a same hospital basis for the quarter, when you normalize the divestitures since last year and risk contracting business in that discount rate item, I mentioned about, we grow our hospital same hospital segment margin 10 bps — 10 basis points.
Okay, that’s helpful. And then just a follow-up question, just going back to sort of the volume side of the equation, obviously, a strong result. A little surprised, I guess not to see the sort of the flow through I guess on the surgery side. So maybe just help us on where you’re seeing the declines now in terms of service lines and how much of that may be just a shift from sort of hospital, the ASC that hurts the optics there? Thanks.
Yeah. Hey, it’s — Ralph, it’s Saum. So obviously, we’re very focused on improving our surgical volumes through many of the same initiatives that I described earlier. That takes a little bit longer frankly as we move from some of the more immediate operational things that allow the full weight of the programs that we have to take hold to improving service levels in many of our operating rooms and other things. When you look at the total surgical volumes, we think Q2 is a sign of strength relative to where we’ve been in the past, and I think that importantly, when you look at the ambulatory surgeries in conjunction with what we’re doing in the hospitals we had significant strength from that standpoint, including in the Tenet hospital markets. So we feel pretty good about the progress we’re making there, there’s obviously a long way to go. And the investments we make in clinical capacity and the technology investments in some of these higher-end service lines will continue to pay off over time.
Okay. Thank you.
We will now take our next question from A.J. Rice of Credit Suisse. Please go ahead.
Hi, everybody. First, just maybe to get you to comment a little more on your comments about free cash flow, even if I normalize, I guess, for some unusual items in the first half, it looks like you are about a positive $43 million, and you’re still holding to a $1,600 million guidance number. What about the back half that gives you some confidence that you’ll see that kind of swing, is that all seasonality? Or are there other things in there?
Good morning, A.J. This is Dan. Absolutely some of it is seasonality. Let me go through just a couple of numbers, so you’re right, $43 million of adjusted free cash flow in the first half of the year. We do have — we’ve talked about this in the past, we have certain annual working capital funding requirements in the first half of the year, namely, where we manage our employees 401-k contributions and our incentive compensation payments. That’s roughly $250 million. So you won’t see that in the back half of the year, obviously, since it’s a one-time year funding. So you start with the $43 million add $250 million to that, we obviously are anticipating earnings growth in the back half of the year of roughly $160 million. So that will contribute to improved free cash flow in the back half of the year. There is some timing issues related to payments from customers just a couple of days here and there between receiving in the quarter versus in the subsequent quarter related to our Conifer business that will be about $40 million of additional cash flows in the back half of the year. We’re anticipating there should be some tax refunds coming in around $15 million there. And then we saw an uptick in days and they are in the first half of the year, which is roughly $90 million to $100 million, we do not expect that to recur in the back half of the year.
So when you start taking those items into consideration. That’s why we feel good about where our free cash flow guidance is for the year. We’re obviously incredibly focused on improving free cash flow generation. It’s not unusual for our free cash flow in the first half of the year to be softer than the back half of the year due to the — certain of thee — there are certain in our working capital annual funding requirements.
Okay. And maybe my follow up would just be around one more swipe at the volume strength. Do you think that — I mean a lot of what you’re describing is the initiatives that you guys have taken and obviously the benefit of divestitures and things like that? Can someone just comment on what you’re seeing in the underlying market tone? Do you believe that there is increasing strength in the volume trend in your underlying markets? And I guess medical in particular since that was particularly strong one, but just generally would you comment on what you think the underlying markets you’re in?
A.J., this is Saum. The underlying, I mean first of all, we — our underlying markets have a number of markets with significant growth both in terms of the population and in recent trends, if you look over the last four or five years from a coverage standpoint, right. So while we appreciate those strengths, a lot of what we’re doing and focused on over time includes taking market share or market share back in many of these markets based upon improving both service lines, but also many of the operational things that we’re focused on which are resulting in some of the early volume strength as we rebuild. As I said over time, the surgical programs and — some of the cardiovascular and other procedure-based programs over time. So again I don’t think from the numbers I see there is any major change in the underlying volume environment in the industry. Certainly, if you look across both the [Indecipherable] and what the large not-for-profit Health Systems are reporting. I don’t see any significant change in trajectory there. I think our focus is more on making sure that we are performing up to the level that we should in each of our markets and probably that is resulting in both riding the trend, but real market share capture, which is our goal.
Okay, great. Thanks a lot.
We will now take our next question from Pito Chickering of Deutsche Bank. Please go ahead.
Good morning, guys. Thanks for taking my questions. You increased the hospital same-store revenue guidance, which implies a stronger back half revenue growth versus the first half, but you didn’t increase the hospital EBITDA guidance. Are there new headwinds on hospital EBITDA that prevented you from raising guidance? Or are you guys just being conservative here?
Hey, Pito, it’s Dan. Good morning. Now listen, it’s early in the year — we’re tracking a little bit of ahead where we thought we’d be from a revenue perspective. But we — it’s a pretty wide range we have out there, so we still believe we’re within that range. We’re obviously target toward the upper half of the range, but we’ll see where we come in the third quarter and then update accordingly at that point.
Yeah, look — this is Ron. I think that this is — at the end of Q2, we’re beginning to see really some very positive things. I’d like to get it through Q3 to make sure the trend is solid and we know where we’re heading before we — so you could call that conservative and realistic or whatever, but we think the ranges were appropriate. So
Okay, great. And then a follow-up here. Watching the — uncompensated care the trends continue to grow to 26.8%. Is this a trend we should be worried about? And can you walk us through what you’re seeing on these trends? And also looking at the self-pay account receivables over 180 days, you seem to be ticking up from 52% in this quarter from 42% at the end of 2018. Can you give us more color on that?
Hey, Pito, it’s Dan. No, listen the uninsured trends have been relatively consistent with what we saw in the first quarter. I would say there’s nothing unusual or surprising. Most of the growth in the uninsured volume are — is related to stage where they did not expand their Medicaid programs. But that’s nothing new. So no, I wouldn’t say there’s anything really unusual.
Great. Thanks so much.
We will now take our next question from Sarah James of Piper Jaffray. Please go ahead.
Thank you. You guys have been really consistently exceeding expectations on the segments where you focused on specifically for turnarounds, and one of the outstanding pieces here is the risk-based contracting. In last quarter, you talked about turning it around to management changes and reevaluating of these contracts makes sense for Tenet going forward. So can you update us on where you are in the process of evaluating those types of contracts? And if you’re seeing any initial signs of improving profits? Thanks.
Hi, Sarah, it’s Dan. Let me address that. Yeah, actually we did see pretty significant improvement in the second quarter in terms of the overall operating results related to that risk contracting business. I think we talked about last quarter that the losses were roughly $10 million or $11 million that came down a fair amount in the second quarter which to a couple of million dollars, which — that’s what we anticipated. We brought — we got new management team in place. We’re going through reevaluating the entire business, the infrastructure, all management levels. And yeah, so far, we’re making pretty good progress and we would expect our second quarter trends to be fairly consistent with what we’re anticipating in the back half of this year.
Got it. And to follow up on that, I guess, just big picture is this type of contracting something that you could see at one point in the future being a contributor to earnings? And is it something that you would want to grow that could be an important part of Tenet strategically long-term?
Well we certainly — we look for opportunities to enter into certain risk arrangements where it makes sense. I would say and that — now listen, this business isn’t necessarily ever going to be significantly material to the company’s overall financial results, but certainly the drag that we saw in the back half of this year and in the first quarter, we don’t anticipate that going forward. And as we continue to evaluate the business and the associated contracts and we will make certain decisions as to what business points we remain in related to that business. So we have it under control and that’s what we work to get to, and that’s — so we’re on track with where we thought we’d be.
And Sarah, this is Saum. The only couple of things, I might add to that is we participate successfully in risk sharing arrangements in some of our markets where there is more delegated risk already we have for years without any difficulty, and we’re also significant participants in government-based risk sharing programs, for example, we’re one of the largest who are in the BPCI program — BPCIA program, which we expect to be successfully executed across our system. So risk-based contracting is a broad term and can apply to a lot of different types of arrangements. Obviously, we’re more selective about what we’re doing at this point, but we also have a track record of success in many, many other risk-based contracting arrangements outside of the one that we’ve referred to over the past quarters that happened to go south.
We will now take our next question from John Ransom of Raymond James. Please go ahead.
Hey, good morning. Obviously, the med/mal expenses a bit elevated this year. Without holding you to a specific prediction, if you look at hospitals that have been divested service lines that have been divested maybe up tiering of physician groups you experience this year. Is that something — it seems to me like we should see that trend ticked down looking at the leading indicators, but I know it’s complicated with rates and actuarial assumptions. But can you give us some handle on how to think about that expense over the next three to five years?
Hey, John, it’s Dan. Good morning. We’re driving toward reducing the levels of med/mal expense on a going forward basis. What we have been doing as you’re aware over the past roughly a year is reevaluating and assessing the current portfolio of claims and we’ve made very conscious decisions to settle various matters. And your point about certain divested markets, yeah, there’s been a couple of markets where we’ve exited where the trends there were higher levels than certainly, we would like. And now that we’ve divested those markets, what people should anticipate over the longer term, as we wouldn’t necessarily have those type of headwinds from a settlement perspective related to those markets.
So, yeah, we’ve talked about as we anticipate at least through the end of this year for our expense levels to remain relatively consistent with what we’ve seen in the first half of this year and the back half of last year. But as we move forward and we obviously haven’t put any numbers out for 2020 or beyond yet, but we are certainly working toward reducing the level of malpractice expense down the road. And it’s a number of different initiatives, we’ve obviously exited some pretty tough markets from a litigation perspective as well as our focus on various service lines where we may not have had the strongest position and we’ve decided to close certain service lines in certain markets. So we’re obviously very focused on and that’s where we’re heading in the future.
Okay. And then look, I know you’re not providing 2020 guidance, but at least in terms of some of the numbers we’ve looked at when you wrap around the cost cuts for a full year and a little bit of EBITDA growth, you’re going to generate, in our model, something like $400 million to $600 million of true free cash flow. What I mean by that is cash that could actually be available to pay down debt. I know you’ve given adjusted free cash flow number, but that’s not really a number that’s going to pay down debt. So as you think about prepping the company for the Conifer spend and priorities between M&A and USPI and just cash debt reduction. How are we thinking about prioritizing those dollars? Thanks.
This is Dan, again, John. Obviously, we are very focused on reducing our debt. We obviously have talked about reducing leverage as well to five times or less. But we are also focused on reducing the absolute dollar amount of debt. And so, when we — as we generate free cash flow and as we make investment decisions. That certainly will be at the top of our mind in terms of allocating capital.
Yeah, this is Ron. Also, listen, I think we’ve made a lot of changes here and we’ve stabilized a lot of, I don’t know the right word is stabilized, but we’ve certainly moved the company forward in a lot of areas fairly quickly. The area that we will put a significant amount of additional interest in now and not that we weren’t interested, but more emphasis from my office through the company will be on cash and where we spend our money and how we spend it even at the lowest level. And it is something that Saum and I are working on together, we’re very committed about and it’s not something that gets resolved in the next quarter. But we do need now to, I think, increase the amount of emphasis and the amount of focus across the entire enterprise on a day-to-day cash management basis that I think we could do a better job at. So and that is all geared toward what we’ve said consistently, which is debt will be addressed through earnings and we will do that through, I think, adding that process to through the entire company. And it’s also something from a Conifer standpoint that there — from a collection standpoint as well as from even where they spend money, you can see the tightening we’ve done there. So we have a lot of focus on that going forward, much more than I think the company has felt in the past, so — because we’re at that point now to take that step. So–
Right. And then last one from me, maybe this is for Saum, but you’ve been in the organization for a while, where do you think you are on a 1 to 10 if you will, in terms of integrating the opportunity between the Tenet legacy hospital systems and the USPI ASCs. And is that, I mean, other companies who’ve done this, they call it, collaboration, if we want to call it a collaboration rate, is that something that there is more potential for in the future. And do you see the company is kind of operating separately today? Or do you think there is value in them being more integrated?
Hey, John, it’s a really good question and I would say that we’re early in that journey. It’s hard to put a number to it. But I would say three to four, if there is a 10 if you want to have a number to it. Look, I think there’s four or five different things from an integration standpoint. The first is obviously market facing opportunities in the Tenet markets with USPI. We embrace ambulatory both from a surgical standpoint, imaging standpoint and obviously the urgent care business that exist there, and we’re very focused on business planning together from the standpoint of what we can do in the markets to expand our ambulatory presence and access points for our patients. So that’s kind of opportunity number one. The question of USPI operating separately or together, I mean, USPI is literally the leading platform with not-for-profit health system partners across the country and there’s a degree of separation that needs to be maintained there both for the integrity of those businesses and the growth prospects that exist in those markets in the way USPI operates with those partners. Our objective at Tenet is to actually match the level of that partnership in our markets that USPI’s achieved with its most successful not-for-profit health system partners, which represents upside for both USPI and tenant as a whole together, and also our clinical community in the markets in which we operate. So there is success to be had all around.
The third component of integration is obviously looking for those functions especially starting in the back office, where we have the ability to capture and create synergies, we’re down that path and we’ll continue down that path over time. And then finally, there are opportunities more from the standpoint of market facing and clinical ventures that we would pursue together. So when we think about things in the future whether they’d be more near-term in terms of how to really approach the opportunity in orthopedics collectively those are immediate opportunities that we expect to have benefit over the next 12 months. And if you think about it over a longer period of time, ambulatory cardiology procedures and other things are areas where we simply just do that planning together as a joint operating management team between myself and Brett and his team in order to capture those opportunities by making a single set of rather than a double set of investments. So going through all those points, there’s a lot of upside here that’s still left from the pathway that we have together.
Great, that’s — go ahead please.
No, that’s OK, it’s Brett. I was just going to do obviously some sport exactly what Saum said, I couldn’t agree more. And I think if you look at just one data point as it relates to how Tenet-USPI are integrating, you don’t have to look very much further than our pipeline. If you look at our pipeline, a number of years ago, there is actually very few de novos and acquisitions in the pipeline that were in the actual Tenet market. If you look at our pipeline today, our pipeline is significantly weighted toward the Tenet hospital markets and that will continue to grow over time. In addition to obviously continuing to sport our 50 plus health system partners across the country. So there is a more healthy balance between the two than there was just a few years ago.
Great. That’s it from me. Thank you.
We will now take our next question from Brian Tanquilut of Jefferies. Please go ahead.
Hey, good morning guys. Congratulations on the quarter. Dan, I guess my question for you, as I think about the — going back to Ralph’s question earlier about margin performance. I mean, even if I back out the $13 million, hospital EBITDA margin up 20 basis points at a 5.3% to 5.6% same-store revenue number. How should we be thinking about your ability to drive leverage. I mean this is a pretty solid same-store performance, so how should we be thinking about your ability to drive that?
Hi, good morning, Brian. This is Dan. Absolutely we believe there is a lot of opportunity to leverage our existing infrastructure in the hospital segment and grow margins. As I mentioned, we’re up in the quarter when you normalize for divestitures from last year and that risk contracting business and the discount rate. It is up 10 bps. We obviously need to do better than that, but we are making improvement. One of the things John mentioned a couple of minutes ago, as we look down the road in terms of our malpractice expense, obviously, we’d be targeting reducing those levels of experience. But as we continue to grow our hospital volumes whether the medical cases or surgical cases, we’ll be able to take advantage of our existing capacity that we have and be able to drive incremental margin. We also are very confident in terms of our ability to execute on our cost reduction initiatives, which right now are $450 million in aggregate. As we move through the back half of this year, we anticipate additional ramp and those efficiencies. And then as we move into the next year, we talked about this $200 million additional of cost efficiencies, we’ll capture about $50 million this year and we’ll capture the rest next year. And listen, we, there is opportunities in terms of integration of various functions across the three business units.
As Saum mentioned, in particular, related to USPI there is still more opportunity for site consolidation. We are consolidating our corporate offices. We continue to be very focused on labor management. We think we’ve been doing a pretty good job in terms of consistent practices and standards across the hospital platform. And in terms of other operating expenses, there’s a lot of additional opportunity there as we continue to renegotiate contracts. We’ve managed contracts better. We rationalized various vendors where we may have multiple different contracts for the same vendor across the portfolio. So we’ve been executing on that. There is automation and centralization and we’ve talked about offshoring, which also will create efficiencies and we’ve also been digging into our IT spend and then we think there’s opportunity there as well in addition what we’ve already executed on. So we think down the road in terms of the hospital business, given our ability to execute on cost efficiencies and grow our volumes. We were optimistic we’ll be able to grow the hospital margins.
I appreciate that. My follow up Dan, as I think about your comment on the California Provider Fee, I know sometime in the second quarter, there is a lot of discussion about that being pushed out. What changed or what gave you that visibility and confidence that we’re going to recognize this $65 million in Q3?
Based on where the process is at this point, with the state working with CMS and where we stay on top of that, we’re very closely monitoring that. And based on where we see things heading here this quarter, we believe we’ll be able to recognize that revenue in the third quarter. So when we look — if you go back three or four months, we didn’t have as much visibility on where the process may be at this point, but we feel pretty good about where things are at. And so at this point we feel good about being able to recognize the revenue in the third quarter. And again, there’s no change to our annual estimate, it’s still $260 million for the year, but $65 million at quarter.
All right. Got it. Thanks, Dan.
We will now take our next question from Whit Mayo of UBS. Please go ahead.
Hey, thanks. Maybe first one for Brett. And then if I could actually see the de novo pipeline for your surgery centers, any common theme there with the type of centers and why systems today are pursuing this strategy with you now. And just curious if you could talk about the size, the position syndicate, service lines, are these all ortho focused? Just anything that stands out to help visualize that the opportunity. Thanks.
Hey, Whit. Sure this is Brett. Yeah, I’d definitely say that our de novo pipeline is accelerating and it’s really a combination that the combination of a number of different factors. First, I mean, I think you’re aware of this, most of the health systems around the country are very focused on accelerating their ambulatory growth, which is resulting in development opportunities and de novo opportunities that’s a way for Tenet as well as our health system partners to enter new markets and a very capital efficient fashion. There is also opportunities to develop de novos on campuses that are being used to move lower complexity cases to a lower cost setting and you combine that with migration of higher complexity surgical cases from hospitals at the ASCs, and we’re seeing increased opportunities for the single-specialty center of excellence in the areas of ortho, spine, etc. So in general, that’s a quick answer to why we see such a strong growth in our de novo pipeline and in terms of the kind of the mix of those de novos, I would say probably half of those are single specialty in nature, again, spine, total joint, ortho and the other are multi-specialty in nature.
That’s helpful. And second question just for Dan. Can we talk a little bit about the seasonality for the acute business, I mean as I sort of reflect back on the last four to five years, you’ve earned a lot more in the first half than you have in the second half and obviously your guidance for the acute segment is much more second half weighted this year. So can you help maybe bridge the gap, because history says that it’s tough to reconcile but I think it’s a little difficult to look at prior years with so much noise with portfolio management? So any help would be great.
Hey, Whit, it’s Dan. In terms of when you think about the seasonality in the business. Obviously, the third quarter is generally the quarter that’s softest in terms of volumes and earnings is due to people on vacations, etc. But when we think about the fourth quarter and really the entire back half of the year, the improving volume trends that we’re seeing give us confidence that we’re going to continue to grow the hospital volumes and ultimately the earnings. We’ve talked also that the upside from the cost efficiencies that we’re executing on are going to be more pronounced in the fourth quarter. So the continued trajectory from a volume perspective, our focus on cost management as well as our pricing yield has been strong and we anticipate to get some lift in back half of the year from pricing as well. So those are some of the key variables why we feel confident and ability to drive the growth in the hospital business in the back half.
All right. Well, maybe one last one just to slip in. Just any changes with state supplemental payments that we should be aware of over the next six months now that we’re in the state fiscal year cycle?
No, nothing major. Obviously, I talked about the California Provider Fee program, but nothing, nothing major at this point.
Okay, great. Thanks.
We will now take our next question from Patrick Rielly of Barclays. Please go ahead.
Thanks, good morning. When we look at the other operating expense line on a same store basis, Conifer’s down $16 million, USPI’s down about $10 million, but the hospital segment is up about $85 million, a little over 10%. Is there anything specific that’s driving that, I know you talked a little bit about med/mal? Can you maybe quantify that increase versus the prior year? Thanks.
Yeah, Patrick, it’s Dan. In terms of the other operating expense line, certainly, that is where malpractice goes through. We do have an outline in the various elements of the increase in other operating expenses in our Form 10-Q and back in the MD&A section. But between med/mal and as we make additional investments to grow our business that’s some of the items flowing through that line. Overall, we feel really good about our cost management. As I mentioned in my prepared remarks, costs were up about 2.9% exclude the discount rate and we continue to execute on our cost reduction initiatives that we’ve talked about. It’s great lengths and there are more opportunities, as I mentioned a few minutes ago, in other operating expense line as we continue to dive in and reevaluate contracts where we have some contracts will probably terminate down the road, where we just got a number of vendors we need to rationalize and start leveraging our scale more across all the business units.
Got it. Thanks. And just a follow-up on the uncompensated care question from earlier. I just wanted — was there any change to your discount or charity care policies for 2019, I just asked because we see that uncompensated care up I think about 300 basis points as a percent of revenue. But it looks like the charity in uninsured volumes are actually down a little bit as a percent of overall volumes. So just curious, is there any change there in those policies or maybe possibly, this is just an impact of the divestitures that we’re seeing in the uncompensated care numbers. Thanks.
Yes, I mean, there hasn’t been any noteworthy change in our policy. I mean we have seen an uptick in the volume to some degree, as I mentioned, predominantly the states that did not expand Medicaid program. But I would the trends that we’ve seen so far this year haven’t been anything that or unexpected actually the transaction in the second quarter sort of moderated from what we saw in the back half of last year. So obviously working with our Conifer colleagues, when uninsured patients do arrive at our facilities. We do a really good job, if they did qualify for insurance coverage through some program such as Medicaid, we do a really good job of getting them covered, our success rate is about 96%. So really strong. So if someone couldn’t get some coverage, we’ll be able to obtain it for them. So, well, we’ll keep working at it, but again nothing particularly unusual.
Mary, we’re going to take one last question and try to end before 10. So people can get on the other call. I know people are looking to join. If you could take the last question, Mary.
Yes, we will now take our final question from Peter Costa of Wells Fargo Securities. Please go ahead.
Thanks for squeezing me in, guys. And sort of a broader question regarding some of the new rate rules that have come out from CMS. First, if you have any comment on transparency. It was in the outpatient PPS rule and then on the inpatient PPS rule, the final rule. The payments are coming down a little bit relative to what the proposed rule was from 4.7 billion increased to a 3.8 billion increase. And I’m curious what was the headwind to you in the fourth quarter for that?
Peter, it’s Dan. Yeah, actually the — let me go through both the final IPPS rule, the inpatient rule and as well as the proposed outpatient rule. From a — the annual rate perspective, the inpatient rule actually came in a little better for us. We estimated to be about 1.4%, which is about $28 million of annual revenue. That’s a little higher than what we were anticipating. When the proposed rule came out, we thought it was going to be in the low $20 million’s, $21 million, $22 million. So got a little bit better, namely on an additional line. On the outpatient rule that’s proposed from a hospital perspective, 2.4% proposal that’s about $15 million of additional outpatient revenues. That’s pretty much in line with where we thought it would be. The ASC rate update that’s been proposed is 2.7% and then there were certain cases that we’ll now be able to be reimbursed on — they’ll be placed on ASC list. So we think that creates opportunities for upside for USPI. So, I would say overall the outpatient pretty much where we thought it would be and the inpatient, a little bit better from the proposed rule.
Great. And then just as a follow-up on the transparency commentary in the outpatient rule?
Yeah, so we are certainly supportive of making the experience for our patient as good as possible and enabling our patients to understand the economics associated with any care that will be provided to them. We — our Conifer team, we have technology in place to help patients estimate how much it will cost them for various procedures and we do a pretty good job looking at their insurance coverage that they have, working with them, understanding their plan, understanding their coverage and estimating what the estimated cost will be. So it is — it’s obviously important to consumers and patients and we’re obviously supportive of making the process as transparent as we can.
Okay. Well, thanks everyone for joining us today. If you have any follow-up questions, you can reach me at 469-893-692. We look forward to speaking with you again either at a — hopefully at a conference in September or on our third quarter call. Thanks.
[Operator Closing Remarks]
More THC analysis” data-reactid=”233″>More THC analysis
All earnings call transcripts” data-reactid=”234″>All earnings call transcripts
Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.” data-reactid=”247″>This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.” data-reactid=”248″>Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Fool.com” data-reactid=”249″>This article was originally published on Fool.com